Bank of America
NGNE icon

Bank of America’s Neurogene NGNE Stock Holding History

Bank of America’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,100
Closed -$231K – 8459
2024
Q4 		$231K Buy
+10,100
New +$376K ﹤0.01% 6046

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Bank of America's NGNE Position: Q2 2026 in Review

Bank of America increased its Neurogene (NGNE) stake by 2.4% in Q2 2026, buying an estimated $7.16K and bringing the position to 11,124 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #5137.

Bank of America first reported a position in NGNE in Q4 2015 and has held it in 37 quarters since. The position peaked at $1.7M in Q3 2024. 111 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Bank of America held 11,124 shares of Neurogene worth $350K as of Q2 2026.
  • Bank of America bought 260 Neurogene shares in Q2 2026, an estimated $7.16K.
  • Neurogene made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5137 holding.
  • Bank of America first reported a position in Neurogene in Q4 2015 and has held it in 37 quarters since.
  • Bank of America's Neurogene position peaked at $1.7M in Q3 2024.
  • 111 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.